Highlights

• Recce Pharmaceuticals upgraded its Australian R327G diabetic foot infection study to a pivotal Phase 3 trial with approval for up to 200 patients.

• The Indonesian registrational Phase 3 trial continues progressing towards enrolment of 310 patients, with an interim analysis planned after 155 patients.

• The company signed a non-binding term sheet for a potential 10-year Middle East and North Africa licensing arrangement, including milestone payments and royalties.

• Cash stood at A$2.90 million as at 30 June 2026, with quarterly operating cash outflows of A$2.17 million.

• Recce Pharmaceuticals shares traded at A$0.36 on 28 July 2026, declining A$0.010 or 2.67% during the session.

Recce Advances Late-Stage Development Strategy

Recce Pharmaceuticals Limited (ASX:RCE) is progressing multiple clinical and commercial initiatives as it advances its synthetic anti-infective technology platform towards potential market approval.

The company is developing R327, a synthetic polymer-based anti-infective designed to target bacterial cell membranes rather than specific biological pathways. Recce believes this mechanism could provide an alternative approach against antibiotic-resistant bacteria.

During 2026, Recce has advanced two Phase 3 clinical programs for R327G, its topical gel formulation targeting diabetic foot infections, while also progressing a potential licensing pathway across Middle Eastern and North African markets.

However, the company remains a development-stage biotechnology business with no commercialised products, making clinical outcomes, regulatory approvals and funding availability key factors for future progress.

Australian R327G Trial Moves Into Phase 3

Recce Pharmaceuticals confirmed in its June 2026 quarterly update that a Human Research Ethics Committee approved a protocol amendment upgrading its Australian R327G diabetic foot infection study from Phase 2 to a pivotal Phase 3 trial.

The updated study design allows enrolment of up to 200 patients and expands eligibility to include moderate infections alongside mild infections.

An interim analysis is planned after approximately half of the participants complete treatment.

At the end of the June quarter, 18 patients had received treatment, with full recruitment expected by the end of 2027.

The Phase 3 study is intended to generate registration-supporting data aligned with regulatory requirements in Australia and potentially other markets.

Indonesian Phase 3 Trial Continues Progress

Recce’s separate Indonesian registrational Phase 3 study is progressing towards enrolment of up to 310 patients.

The trial is evaluating R327G gel against placebo across activated clinical sites, with an interim analysis planned once 155 patients complete treatment.

Indonesia’s medicines regulator completed an inspection without findings that would prevent continuation of the study.

Recce has indicated that regulatory approval in Indonesia is anticipated during calendar 2026, although timing remains dependent on clinical outcomes and regulatory review.

MENA Licensing Agreement Provides Commercialisation Pathway

Recce disclosed a non-binding term sheet with a Middle Eastern pharmaceutical company covering a potential 10-year exclusive licensing arrangement.

The proposed licence would cover markets including Saudi Arabia, Gulf Cooperation Council countries, Iraq, Egypt, Algeria and Morocco.

Indicative commercial terms include:

  • Up to US$3.5 million in upfront and milestone payments.
  • 30% of net selling price.
  • Additional 6% royalty above US$50 million in annual net sales.

The proposed treatment price referenced by the company is approximately US$1,500 per course.

The agreement remains subject to due diligence, final documentation and regulatory approvals. No binding licence has been completed.

Understanding Recce’s Technology Platform

Recce’s platform consists of fully synthetic polymer anti-infective compounds designed to disrupt bacterial cell membranes.

The company’s key programs include:

  • R327G: A topical gel formulation being developed for diabetic foot infections and skin infections.
  • Intravenous R327: Targeting serious infections including sepsis, bloodstream infections and complicated urinary tract infections.
  • Inhaled and intranasal formulations: Earlier-stage development programs.

The company’s strategy is to establish initial regulatory approval in selected markets and use clinical data to support expansion into additional territories.

Indonesia represents the near-term regulatory pathway, while potential MENA licensing provides a possible commercial expansion route.

Financial Position and Funding Requirements

Recce remains dependent on external funding while progressing clinical programs.

The June quarter Appendix 4C showed net operating cash outflows of A$2.17 million, including A$1.55 million allocated towards research and development activities.

For FY26, total cash outflows were A$10.02 million.

Cash at 30 June 2026 was A$2.90 million.

The company reported total available funding of A$23.63 million, including cash and unused financing facilities. However, this figure includes undrawn debt facilities rather than only available cash.

Recce also received a A$3.67 million Australian Taxation Office refund after quarter-end, comprising R&D tax incentive and interest components.

The company completed a A$4 million placement at A$0.40 per share in July 2026 and launched a share purchase plan targeting additional funds.

Funds raised are intended to support clinical trials, commercial licensing activities, IND-enabling work and general working capital requirements.

Why the Development Matters

The upgrade of the Australian study to Phase 3 represents a significant milestone because it moves R327G into a registration-focused clinical pathway.

A successful pivotal trial could provide data supporting regulatory submissions, while the interim analysis creates an earlier decision point before full trial completion.

The MENA licensing opportunity could provide a commercial pathway without requiring Recce to build its own distribution infrastructure across the region.

However, the proposed agreement remains non-binding, and commercial value depends on regulatory approvals, market adoption and execution of final agreements.

Potential Growth Catalysts

• Interim results from the Indonesian Phase 3 study after 155 patients.

• Potential Indonesian regulatory approval for R327G during calendar 2026.

• Conversion of the MENA term sheet into a binding licensing agreement.

• Progress towards the Australian Phase 3 interim analysis after 100 patients complete treatment.

• Future submission of an Investigational New Drug application to the US FDA.

Risks and Challenges

Funding remains one of the key challenges for Recce. The company had A$2.90 million in cash at 30 June 2026 against quarterly operating outflows exceeding A$2 million.

Future clinical development, regulatory activities and commercial preparation may require additional capital.

Clinical risk also remains significant. Both Phase 3 programs are evaluating R327G in diabetic foot infections, meaning unsuccessful results could affect multiple development pathways.

Commercial adoption may also present challenges, as diabetic foot infections are commonly treated with existing low-cost antibiotics. Demonstrating improved outcomes and achieving reimbursement acceptance will be important for future market penetration.

The MENA licensing arrangement is still non-binding, and completion depends on due diligence, negotiations and regulatory requirements.

What Investors Should Watch Next

Key upcoming developments include:

• Indonesian Phase 3 interim data and regulatory progress.

• Cash position following recent capital raising activities.

• Australian Phase 3 enrolment progress towards the 100-patient interim analysis.

• Completion of a definitive MENA licensing agreement.

• Any future US regulatory pathway updates.

Conclusion

Recce Pharmaceuticals is progressing multiple initiatives aimed at moving R327G from clinical development towards commercialisation.

The Australian Phase 3 upgrade, Indonesian registrational trial and potential MENA licensing arrangement provide several pathways for future growth.

However, the company remains in a high-risk development stage, with clinical outcomes, regulatory approvals and funding requirements likely to determine the pace of progress.

The remainder of 2026 will be important as Recce seeks clinical validation and converts development milestones into potential commercial agreements.